Dennis Cho Sells 531 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 531 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $15,797.25. Following the completion of the sale, the insider now owns 105,318 shares of the company's stock, valued at $3,133,210.50. The trade was a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, May 5th, Dennis Cho sold 689 shares of Twist Bioscience stock. The shares were sold at an average price of $37.65, for a total value of $25,940.85.
• On Wednesday, April 2nd, Dennis Cho sold 124 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $4,802.52.
• On Thursday, March 20th, Dennis Cho sold 230 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total value of $9,586.40.
• On Friday, March 14th, Dennis Cho sold 92 shares of Twist Bioscience stock. The stock was sold at an average price of $40.05, for a total value of $3,684.60.
• On Thursday, March 6th, Dennis Cho sold 277 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $11,332.07.

Twist Bioscience Stock Performance

NASDAQ:TWST traded up $0.10 during trading on Friday, reaching $28.26. The company's stock had a trading volume of 568,367 shares, compared to its average volume of 1,097,730. Twist Bioscience Co. has a 12 month low of $27.12 and a 12 month high of $60.90. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -8.36 and a beta of 2.54. The firm has a 50 day moving average of $36.96 and a 200-day moving average of $42.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc increased its holdings in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the period. Banque Transatlantique SA purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at approximately $43,000. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at approximately $58,000.

Wall Street Analyst Weigh In

TWST has been the subject of a number of recent research reports. The Goldman Sachs Group decreased their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. dropped their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, Barclays lowered their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.